Polymorphism in methylenetetrahydrofolate reductase gene: Its impact on plasma homocysteine levels and carotid atherosclerosis in esrd patients receiving hemodialysis

Nephron

Volumn 87, Issue 3, 2001, Pages 249-256

  Lim, Paik Seong ^a   Hung, Wan Ru ^a   Wei, Yau Huei ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Carotid atherosclerosis; Hemodialysis; Hyperhomocysteinemia; Methylenetetrahydrofolate reductase gene

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; HOMOCYSTEINE; PYRIDOXINE;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMMON CAROTID ARTERY; CONTROLLED STUDY; CORRELATION FUNCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR;

ADULT; AGED; ALLELES; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POINT MUTATION; POLYMORPHISM, GENETIC; RENAL DIALYSIS;

EID: 0035065689     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045922     Document Type: Article

References (46)

1. Hyperhomocysteinemia, an independent risk factor for vascular disease
2. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease
3. Plasma homocysteine in renal failure
4. The role of homocysteine in end-stage renal disease
5. Homocysteinemia and vascular disease in end-stage renal disease
6. Hy-perhomocysteinemia is a risk factor for atherosclerosis in chronic uremic patients
7. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study
8. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients
9. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
10. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology and potential relationship to arteriosclerotic outcomes
11. Clinical chemistry and molecular biology of homocysteine metabolism: An update
12. Hyperhomocysteinemia and end-stage renal disease
13. Thermolabile methylenetetrahydrofolate reductase: An inherited risk factor for coronary artery disease
14. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
15. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients
16. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection
17. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardiac infarction in US physicians
18. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The result of a meta-analysis
19. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): Its frequency and impact on plasma homocysteine in different European populations
20. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese
21. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentrations
22. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms and B vitamins
23. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
24. Homocysteine and folate concentrations in blood from patients treated with hemodialysis
25. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease
26. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients
27. Hyperhomocysteinemia is a cause of vascular occlusion in end-stage renal disease
28. Hy-perhomocysteinemia in dialysis patients and homocysteine clearances of different hemodialyzers
29. 6 and hemodialysis: The impact of high-flux/high-efficiency dialysis and review of literature
30. Effect of folic acid and betaine on fasting and post-methionine-loading plasma homocysteine and methionine levels in chronic hemodialysis patients
31. Plasma homocysteine and cardiovascular disease
32. Sulphur containing amino acids in chronic renal failure with particular reference to homocysteine and cysteine-homocysteine mixed disulphide
33. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/l)
34. 12 and on the risk of premature atherosclerosis
35. Genetic analysis of the thermolabile variant of 5,10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke
36. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease
37. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease
38. Methylenetetrahydrofolate reductase gene and coronary artery disease
39. Thermolabile methylenetetrahydrofolate reductase on coronary artery disease
40. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study
41. Association between elevated plasma homocysteine and increased common carotid artery wall thickness
42. Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia
43. Evaluation of the presence of premature atherosclerosis in adults with heterozygosity for cystathionine-β-synthase deficiency
44. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis
45. Homocysteine and short-term risk of myocardiac infarction and stroke in the elderly. The Rotterdam Study
46. Plasma homocysteine as a risk factor for vascular disease